Siddharth VelmankarLeadership review 2026

Siddharth Velmankar · Chief Product Officer · India

The move into equipment enlarged the physical assumptions I needed to question.

Jul 2021 — Present

Chief Product Officer

Pravellen Devices

Sector
Laboratory and healthcare workflow equipment
Ownership
Private company; founders 58%, investment fund 42%
Company scale
₹1260 crore company revenue in FY 2025–26
Employees
2600 company employees at October 2026
Geography
Pune headquarters; equipment for Indian laboratory and healthcare settings
Reporting to
Chief Executive Officer
Team
96 product colleagues through six direct reports at October 2026
Financial scope
₹31 crore delegated FY 2026–27 function expense; manufacturing, engineering and service budgets separately owned

Mandate

Define equipment propositions whose physical scope, configuration and installation conditions remain coherent in the intended workplace.

Outcomes

  • Selected a 580-millimetre workstation design after research showed restricted bench depth; eleven of sixteen site reviews accepted the arrangement.
  • Introduced a twelve-part accessory core with explicit options, with fifty-eight core and thirty-eight extended selections in the ninety-six-site pilot.
  • Retained seventy-three installed and seventeen pending units in the 2025 staged ninety-unit installation pilot.

Decisions in context

I use the CPO remit to make the conditions of a useful equipment offer visible across the portfolio. A compact model, a selected accessory set and a staged installation each require a different account of what the customer is accepting. My delegation funds product work rather than the whole company’s development, manufacturing or service activity. Specialist technical, clinical, quality and regulatory conclusions remain separately owned. I have presented product matters to the board from July 2021, without a statutory appointment in this fictional record. The current cases keep sites needing another configuration and installations still pending within the account. That makes the product decision assessable without pretending that a narrower offer has removed every dependency or produced an unmeasured clinical or commercial benefit for all customers.

Reason for the move

Appointed to lead the product function after six years overseeing healthcare-workflow products; remains in post.

Jul 2015 — Jun 2021

Vice-president of healthcare-workflow products

Pravellen Devices

Sector
Healthcare storage and workflow equipment
Ownership
Private founder-led company with investment-fund participation
Company scale
₹840 crore company revenue in FY 2019–20
Employees
1800 company employees in FY 2019–20
Geography
Pune-led product range serving Indian healthcare workplaces
Reporting to
Executive responsible for the equipment portfolio
Team
61 product colleagues through five direct reports in FY 2019–20
Financial scope
₹18.4 crore annual product-function expense in FY 2019–20; factory and field-service allocations separate

Mandate

Turn observed differences in workplace storage and equipment use into a manageable product range.

Outcomes

  • Used sixty-four site audits to identify twenty-nine settings requiring storage for bulky sealed packs.
  • Supported ₹4.2 crore work on a cabinet with twelve fixed and twelve adjustable compartments.
  • Recorded thirteen accepting and five needing oversized storage in the eighteen-site configuration pilot.

Decisions in context

The vice-president appointment required me to choose where a common product could accommodate variation and where the range needed an explicit limit. The cabinet programme showed why an attractive compartment count did not fully describe useful capacity. I worked with engineering, manufacturing and site colleagues to understand the physical packs and tasks before defending the original uniform arrangement. The mixed prototype remained bounded: five pilot sites needed more than it offered. I kept that need visible rather than call every non-selection a temporary objection. The remit included product expense and colleagues, not authority to infer sterility, infection-control or clinical outcomes from a storage decision. This period prepared me to lead a broader portfolio by making the limits of one configuration part of the product conversation.

Reason for the move

Moved into the CPO role as responsibility expanded across the equipment proposition and its customer dependencies.

Apr 2008 — Jun 2015

Product Director

Pravellen Devices

Sector
Laboratory and healthcare workflow products
Ownership
Private founder-led equipment company
Company scale
₹310 crore company revenue in FY 2013–14
Employees
850 company employees in FY 2013–14
Geography
Pune-based equipment development and domestic customer sites
Reporting to
Head of the healthcare equipment business
Team
34 product colleagues through four direct reports in FY 2013–14
Financial scope
₹8.6 crore annual product expense in FY 2013–14; engineering and manufacturing expenditure under separate owners

Mandate

Establish product briefs grounded in the user’s physical task and the setting around the equipment.

Outcomes

  • Introduced site-context questions into product briefs before feature arrangements were selected.
  • Separated product choices from engineering evaluation and relevant quality, clinical and regulatory assessments.
  • Developed configuration discussions that retained the requirements a proposed common model did not meet.

Decisions in context

Moving from pharmaceutical packaging into equipment changed the scale of the physical assumptions around a product. A pack could be examined on a work surface, while a workstation or cabinet had to coexist with the customer’s available space, access and surrounding sequence of work. I brought the habit of observing the complete task, while learning the different technical and service responsibilities in the new business. The director designation was an executive title, not a place on the statutory board. My role was to define and prioritise the proposition with colleagues who retained their own specialist authority. I avoided treating a more extensive specification as evidence of a better fit before the actual setting had been considered. The move broadened my product judgement rather than transferring a ready-made answer from packaging.

Reason for the move

Promoted to lead healthcare-workflow products after developing the workplace-based product approach.

Jul 2001 — Mar 2008

Packaging Product Manager

Tervanil Therapeutics

Sector
Pharmaceutical packaging development within a therapeutic-products company
Ownership
Private Indian pharmaceutical company
Company scale
₹620 crore company revenue in FY 2006–07
Employees
1900 company employees in FY 2006–07
Geography
Indian pharmaceutical packaging programmes and supervised development studies
Reporting to
Head of packaging development
Team
21 colleagues through three direct reports in FY 2006–07
Financial scope
₹3.2 crore annual function expense in FY 2006–07; quality and regulatory decisions separately owned

Mandate

Choose packaging-product approaches that make the defined handling task understandable and assessable.

Outcomes

  • Owned the symmetric outer-carton prototype in which fourteen of thirty-six participants were confused at first opening.
  • Supported ₹68 lakh development of an asymmetric opening cue using dummy materials.
  • Retained further review after five of thirty participants still showed confusion in the revised prototype study.

Decisions in context

Product management gave me responsibility for selecting an approach rather than only reporting observations. The opening-cue mistake revealed how easily my preference for a consistent appearance could displace the user’s first task. I accepted Rohan Kelvarne’s challenge and supported rework without presenting the revised prototype as a complete resolution. The two studies had different participant groups, and neither established a clinical result. Quality and regulatory colleagues retained the assessments relevant to their mandates. The experience made me more careful about what a demonstration supplies through explanation and what the object itself communicates. It also gave me a concrete error to carry into later leadership, where asking others to reconsider a preferred design would be less credible if my own mistaken approval disappeared from the account.

Reason for the move

Joined Pravellen to apply task-based product work in laboratory and healthcare equipment.

Jul 1994 — Jun 2001

Packaging-development Analyst

Tervanil Therapeutics

Sector
Pharmaceutical packaging analysis and development support
Ownership
Private Indian pharmaceutical company
Company scale
₹180 crore company revenue in FY 1999–2000
Employees
780 company employees in FY 1999–2000
Geography
India; supervised packaging-development work
Reporting to
Packaging-development manager
Team
Member of a ten-person analytical group; no management responsibility
Financial scope
No spending delegation; supported observations and documentation within approved development work

Mandate

Describe the packaging task and the evidence needed to connect a specification with its intended use.

Outcomes

  • Recorded handling sequences and questions for the supervising product and development colleagues.
  • Learned to distinguish a drawing’s physical description from the participant’s understanding of the task.
  • Supported documented observations without claiming authority over a product release or specialist assessment.

Decisions in context

I began in July 1994 after completing mechanical engineering studies that May. The analytical group gave me supervised work in observing how a packaging specification related to the sequence around it. I did not manage the group, approve changes or control expenditure. My contribution was to make the task and the unanswered questions clear enough for the responsible colleagues to examine. That distinction matters because the later product title should not be projected backwards onto an early career. I learned that an observation can be useful without establishing a wider conclusion, and that a well-described object can still leave the first action unclear. The move into management came with responsibility for choices I had previously helped others understand, including the possibility that my preferred answer would need correction.

Reason for the move

Appointed packaging product manager after developing analytical and task-observation experience.

What I am looking for next

I would consider a first board role where experience of healthcare-workflow product decisions adds a useful view of the company’s promises and customer dependencies. The contribution would concern the relationship between the specification, the setting and the work required to make an offer useful. It would not replace clinical, regulatory, engineering or financial expertise, and it would need to be expressed through collective oversight rather than direct product management.

My existing board exposure consists of executive presentations from July 2021. I have no statutory appointment in the fictional chronology and claim no databank registration or exemption. Preparation, employer agreement and disclosure of relevant relationships would come before an institution’s assessment. Twenty-four days a year would be provisional until the role’s actual demands were understood. I would bring the bench-fit decision and the unresolved opening-cue correction as evidence of how I question a product claim, while expecting the new company to test whether that experience is relevant to its own circumstances. The next chapter should begin with that enquiry, not with a title assumed to settle readiness.